The US affiliate of specialty pharmaceutical company Indivior has launched an authorised generic version of Suboxone (buprenorphine and naloxone) sublingual film, a prescription medicine developed to treat of opioid dependence, in the United States, it was reported yesterday.

Sandoz will market the authorised generic version of Suboxone on behalf of Indivior in the US.

Indivior stated that its decision is based on the market impact expected from the anticipated at risk launch of a generic buprenorphine film product in the US by Dr Reddy's Laboratories and Alvogen Pine Brook.

On 19 February, the US Supreme Court rejected Indivior's motion to stay issuance of the mandate vacating the preliminary injunction (PI) granted against Dr Reddy's. Later, the US District Court for the District of New Jersey passed orders to dissolve the temporary restraining order against Alvogen and confirming the PI against Dr Reddy's had been vacated.

The court decision allows Dr Reddy's and Alvogen to sell or import their generic buprenorphine/naloxone sublingual film products.